High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects

Acta Diabetologica

Volumn 51, Issue 5, 2014, Pages 705-713

  Sesti, G ^a   Andreozzi, F ^a   Fiorentino, T V ^a   Mannino, G C ^a   Sciacqua, A ^a   Marini, M A ^b   Perticone, F ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Insulin sensitivity; Intima media thickness; Irisin; Vascular atherosclerosis

Indexed keywords

CYTOKINE; INSULIN; IRISIN; UNCLASSIFIED DRUG; FIBRONECTIN; FNDC5 PROTEIN, HUMAN; GLUCOSE BLOOD LEVEL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; B SCAN; CARDIOMETABOLIC RISK; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE RELEASE; DISEASE ASSOCIATION; DISPOSITION INDEX; FAT MASS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN STIMULATED GLUCOSE DISPOSAL; MAJOR CLINICAL STUDY; MALE; MATSUDA INDEX; METABOLIC PARAMETERS; RISK ASSESSMENT; BLOOD; CAUCASIAN; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED;

ADULT; ATHEROSCLEROSIS; BLOOD GLUCOSE; CAROTID INTIMA-MEDIA THICKNESS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FIBRONECTINS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED;

EID: 84919487162     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-014-0576-0     Document Type: Article

References (36)

1. Ogden CL, Carroll MD, Kit BK, Flegal KM (2012) Prevalence of obesity in the United States, 2009–2010. NCHS Data Brief 82:1–8
2. Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645
3. Prospective Studies Collaboration, Whitlock G, Lewington S et al (2009) Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet 73:1083–1096
4. Meigs JB, Wilson PW, Fox CS et al (2006) Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab 91:2906–2912
5. Arnlöv J, Ingelsson E, Sundström J, Lind L (2010) Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 121(2):230–236
6. Ford ES (2005) Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28:1769–1778
7. Reaven G (1988) Role of insulin resistance in human disease. Diabetes 37:1595–1607
8. Tuomilehto J, Lindström J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
9. Pedersen BK, Febbraio MA (2012) Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat Rev Endocrinol 8:457–465
10. Boström P, Wu J, Jedrychowski MP et al (2012) A PGC1-a-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481:463–468
11. Timmons JA, Baar K, Davidsen PK, Atherton PJ (2012) Is irisin a human exercise gene? Nature 488:E9–E10
12. Huh JY, Panagiotou G, Mougios V et al (2012) FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism 61:1725–1738
13. Hee Park K, Zaichenko L, Brinkoetter M et al (2013) Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab 98:4899–4907
14. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF (2013) Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity–correlation with body mass index. Peptides 39:125–130
15. Liu JJ, Wong MD, Toy WC et al (2013) Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complicat 27:365–369
16. Moreno-Navarrete JM, Ortega F, Serrano M et al (2013) Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab 98:E769–E778
17. Choi YK, Kim MK, Bae KH et al (2013) Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract 100:96–101
18. Staiger H, Böhm A, Scheler M et al (2013) Common genetic variation in the human FNDC5 locus, encoding the novel muscle-derived ‘browning’ factor irisin, determines insulin sensitivity. PLoS One 25(8):e61903
19. Staiger H, Stančáková A, Zilinskaite J et al (2008) A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations: results from the EUGENE2 study. Diabetes 57:514–517
20. Stancáková A, Pihlajamäki J, Kuusisto J et al (2008) SNP rs7754840 of CDKAL1 is associated with impaired insulin secretion in non-diabetic offspring of type 2 diabetic subjects (the EUGENE2 study) and in a large sample of men with normal glucose tolerance. J Clin Endocrinol Metab 93:1924–1930
21. Marini MA, Succurro E, Frontoni S et al (2012) Insulin sensitivity, β-cell function, and incretin effect in individuals with elevated 1-h postload plasma glucose levels. Diabetes Care 35:868–872
22. Marini MA, Frontoni S, Mineo D et al (2003) The Arg972 variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 88:3368–3371
23. Succurro E, Marini MA, Arturi F et al (2009) Elevated one-hour post-load plasma glucose levels identifies subjects with normal glucose tolerance but early carotid atherosclerosis. Atherosclerosis 207:245–249
24. Marini MA, Frontoni S, Succurro E et al (2013) Insulin clearance is associated with carotid artery intima–media thickness. Atherosclerosis 229:453–458
25. Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA (2007) Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. Diabetes Care 30:89–94
26. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (2003) Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167
27. Faber OK, Christensen K, Kehlet H, Madsbad S, Binder C (1981) Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 53:618–621
28. Marini MA, Frontoni S, Succurro E et al (2013) Decreased insulin clearance in individuals with elevated 1-h post-load plasma glucose levels. PLoS One 8:e77440
29. Mittelman SD, Van Citters GW, Kim SP et al (2000) Longitudinal compensation for fat-induced insulin resistance includes reduced insulin clearance and enhanced β cell response. Diabetes 49:2116–2125
30. O’Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK Jr (1999) Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 340:14–22
31. Nigro J, Osman N, Dart AM, Little PJ (2006) Insulin resistance and atherosclerosis. Endocr Rev 27:242–259
32. Madonna R, Pandolfi A, Massaro M, Consoli A, De Caterina R (2004) Insulin enhances vascular cell adhesion molecule-1 expression in human cultured endothelial cells through a pro-atherogenic pathway mediated by p38 mitogen activated protein-kinase. Diabetologia 47:532–536
33. Madonna R, De Caterina R (2009) Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. Thromb Haemost 101:345–350
34. Koh YJ, Park BH, Park JH, Han J, Lee IK, Park JW, Koh GY (2009) Activation of PPARγ induces profound multilocularization of adipocytes in adult mouse white adipose tissues. Exp Mol Med 41:880–895
35. Daniele G, Guardado Mendoza R et al (2014) The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitus. Acta Diabetol 51:123–131
36. Tripathy D, Daniele G, Fiorentino TV et al (2013) Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3–TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56:2153–2163